Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | ATP4A | P20648 | 1/20 | 0.39 |
| ▸ | ATP4B | P51164 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | IAPP | P10997 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BID | P55957 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155003 | 0.93 | GABRA1 (0.39) | GABRA1GABRB2DAOIAPPELANE | |
| SCHEMBL262868 | 0.88 | GABRA1 (0.55) | GABRA1GABRB2ATP4AATP4BELANE | |
| SCHEMBL1332031 | 0.88 | GABRA1 (0.55) | GABRA1GABRB2ATP4AATP4BELANE | |
| SCHEMBL3958175 | 0.87 | BID (0.45) | GABRA1GABRB2IAPPELANECTSG | |
| SCHEMBL841964 | 0.86 | GABRA1 (0.39) | GABRA1GABRB2DAOIAPPELANE | |
| SCHEMBL28967677 | 0.85 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BELANE | |
| SCHEMBL30319989 | 0.85 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BELANE | |
| SCHEMBL28144550 | 0.85 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BELANE | |
| Hydrochloric Acid SCHEMBL625383 | 0.85 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BELANE | |
| Methane SCHEMBL28083182 | 0.85 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118974107-A | Maleimide compound, curable resin composition, cured product thereof, amine compound, and reactant of amine compound and maleic anhydride | 日本化药株式会社 | 2024-11-15 | — | — | CN | disclosed |
| CN-113260646-B | Aromatic amine resin, maleimide resin, curable resin composition, and cured product thereof | 日本化药株式会社 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023189411-A1 | MALEIMIDE COMPOUND, CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF, AMINE COMPOUND AND REACTION PRODUCT OF AMINE COMPOUND WITH MALEIC ANHYDRIDE | 日本化薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023074169-A1 | PRIMER LAYER-FORMING COMPOSITION, LAMINATE, AND METHOD FOR DECOMPOSING LAMINATE | 日産化学株式会社 | 2023-05-04 | — | — | WO | disclosed |
| CN-113260646-A | Aromatic amine resin, maleimide resin, curable resin composition, and cured product thereof | 日本化药株式会社 | 2021-08-13 | — | — | CN | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| WO-2020213640-A1 | AROMATIC-AMINE RESIN, MALEIMIDE RESIN, CURABLE RESIN COMPOSITION, AND CURED OBJECT OBTAINED THEREFROM | 日本化薬株式会社 | 2020-10-22 | — | — | WO | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-9673408-B2 | Luminescent diazabenzimidazole carbene metal complexes | UDC IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-4491672-A | Preparation of aromatic azomethines | BASF AKTIENGESELLSCHAFT (DE) | 1985-01-01 | — | — | US | disclosed |
| EP-0120221-A1 | Process for the preparation of 7-alkyl indoles | LONZA AG (CH) | 1984-10-03 | — | — | EP | disclosed |
| US-4418209-A | ANTIULCER, ANTIARRYTHMIC, ANTIDIARRHEAL, ANTISPASMODIC, ANTIPARASITIC, AND ANTISECRETORY AGENTS | WILLIAM H. RORER, INC. (US) | 1983-11-29 | — | — | US | disclosed |
| US-4401833-A | Process for the preparation of 4-chloro-2,6-dialkylanilines | BAYER AKTIENGESELLSCHAFT (DE) | 1983-08-30 | — | — | US | disclosed |
| EP-0021039-B1 | PROCESS FOR PREPARING AROMATIC AZOMETHINES | BASF Aktiengesellschaft (DE) | 1983-02-09 | — | — | EP | disclosed |
| US-4326075-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| EP-0021039-A2 | Process for preparing aromatic azomethines | BASF Aktiengesellschaft (DE) | 1981-01-07 | — | — | EP | disclosed |
| US-4203920-A | ANTIDIARRHEAL | WILLIAM H. RORER, INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4060635-A | Amidinoureas for treating diarrhea | WILLIAM H. RORER, INC. (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | GABRA1 1655/4885GABRB2 2375/4885ATP4A 3695/4885 |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | GABRA1 1646/4885GABRB2 2159/4885ATP4A 3559/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | GABRA1 1646/4885GABRB2 2159/4885ATP4A 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.